<DOC>
	<DOCNO>NCT02858232</DOCNO>
	<brief_summary>Multiple Target Antigen Stimulating Cell Therapy ( MASCT-I ) new immunotherapy dendritic cell ( DC ) induce autologous peripheral blood . The DC load antigens re-infused . In vitro , antigen-pulsed DC stimulate autologous T-cell proliferation induction autologous specific cytotoxic T-cells ( CTL ) ，similarly re-infused . The previous research data show MASCT modest overall response less adverse effect Hepatocellular Carcinoma patient . The study aim evaluate safety MASCT-1 patient advance solid tumor .</brief_summary>
	<brief_title>MASCT-I Treatment Advanced Solid Tumor</brief_title>
	<detailed_description>This study divide two stage . The first stage safety study small sample , second stage sample size expansion phase . 40-50 patient advanced recurrent solid tumor fail standard treatment recruit study .</detailed_description>
	<criteria>1 . Patients histologicallyconfirmed , advance ( unresectable ) solid tumors（Lung cancer , colon cancer , prostate cancer , soft tissue sarcoma , rare tumor） progress standard therapy . 2 . With write informed consent sign voluntarily patient . 3 . The time Patients enrollment end antitumors therapies≥1 month . 4 . ECOG≤2 . 5 . At least one measurable lesion define RECIST criterion 1.1 tumor . 6 . Life expectancy ≥6 month . 7 . With normal cardiopulmonary function . 8 . Patients adequate organ function define follow criterion : Hemoglobin ( HGB ) ≥85g/L Absolute neutrophil count ( ANC ) ≥1.0×10^9/L White blood cell ( WBC ) ≥3.0×10^9/L Platelet count ≥80×10^9/L Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) ≤2.5 upper normal limitation ( UNL ) ≤5 UNL case liver metastasis Alkaline phosphatase ( ALP ) ≤2.5 UNL Total bilirubin ( TBil ) ≤1.5 UNL Blood urea nitrogen ( BUN ) Creatinine ( Cr ) of≤1.5 UNL Albumin ( ALB ) ≥30g/L 1 . Pregnant expect pregnant 2 . Participated clinical trial screen except observational study . 3 . Refused provide blood sample . 4 . Known allergic history sodium citrate drug . 5 . Known history organ transplant , include autologous bone marrow transplantation peripheral stem cell transplantation . 6 . Known active brain metastasis 7 . The use immunosuppressive drug current 14 day enrollment . 8 . Active primary immune deficiency . 9. known history tuberculosis . 10 . Active infection , include hepatitis B , hepatitis C virus , human immunodeficiency virus . 11 . Patients serious infection , hepatopathy , nephropathy , respiratory disease , cardiovascular disease incontrollable diabetes , etc . 12 . Patients malignant tumor within 5 year , exclude melanoma carcinoma situ cervix . 13 . Clinical sign heart disease . 14 . Treatment antitumors agent within 28days first administration study treatment . 15 . The research influence non legal person , medical ethical reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>MASCT-I</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>